10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________ 

FORM 10-Q

__________________________________

(Mark One)

ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2014

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	FOR THE TRANSITION PERIOD FROM              TO

Commission file number: 000-50789

__________________________________ 

Digirad Corporation

(Exact name of registrant as specified in its charter)

__________________________________ 

Delaware	33-0145723
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
1048 Industrial Court, Suwanee, GA	30024
(Address of Principal Executive Offices)	(Zip Code)

(858) 726-1600

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	x

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes No ý

As of April 21, 2014 the registrant had 18,504,279shares of Common Stock ($0.0001 par value) outstanding.

DIGIRAD CORPORATION

TABLE OF CONTENTS

IMPORTANT INFORMATION REGARDING FOWARD-LOOKING STATEMENTS	3
PART I. FINANCIAL INFORMATION	4
Item 1. Financial Statements	4
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3. Quantitative and Qualitative Disclosures about Market Risk	18
Item 4. Controls and Procedures	18
PART II. OTHER INFORMATION	20
Item 1. Legal Proceedings	20
Item 1A. Risk Factors	20
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3. Defaults Upon Senior Securities	20
Item 4. Mine Safety Disclosures	20
Item 5. Other Information	20
Item 6. Exhibits	21
EXHIBIT 31.1
EXHIBIT 31.2
EXHIBIT 32.1
EXHIBIT 32.2
EXHIBIT 101.INS XBRL Instance Document
EXHIBIT 101.SCH XBRL Taxonomy Extension Schema Document
EXHIBIT 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
EXHIBIT 101.LAB XBRL Taxonomy Extension Label Linkbase Document
EXHIBIT 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
EXHIBIT 101.DEF XBRL Taxonomy Extension Definition Linkbase Document

2

Important Information Regarding Forward-Looking Statements

Portions of this Quarterly Report on Form 10-Q (including information incorporated by reference) include “forward-looking statements” based on our current beliefs, expectations and projections regarding our business strategies, market potential, future financial performance, industry and other matters. This includes, in particular, “Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report on Form 10-Q as well as other portions of this Quarterly Report on Form 10-Q. The words “believe,” “expect,” “anticipate,” “project,” “could,” “would,” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause our actual results to differ materially from those projected, anticipated or implied in the forward-looking statements. The most significant of these risks, uncertainties and other factors are described in “Item 1A—Risk Factors” of this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission on March 20, 2014. Except to the limited extent required by applicable law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

3

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

DIGIRAD CORPORATION

CONDENSED CONSOLIDATED STATEMENTS

OF COMPREHENSIVE LOSS

(Unaudited)

	Three Months Ended March 31,
(in thousands, except per share data)	2014			2013
Revenues:
Diagnostic Services	$	9,555		$	8,939
Diagnostic Imaging	3,442			2,607
Total revenues	12,997			11,546
Cost of revenues:
Diagnostic Services	7,534			6,825
Diagnostic Imaging	2,021			1,904
Total cost of revenues	9,555			8,729
Gross profit	3,442			2,817
Operating expenses:
Research and development	—			818
Marketing and sales	1,095			1,236
General and administrative	1,995			2,102
Amortization of intangible assets	66			66
Restructuring charges	441			1,004
Total operating expenses	3,597			5,226
Loss from operations	(155		)	(2,409		)
Other income (expense):
Interest and other income, net	17			22
Interest expense	(8		)	—
Total other income	9			22
Loss before income taxes	(146		)	(2,387		)
Income tax expense	(2		)	(32		)
Net loss	$	(148	)	$	(2,419	)
Net loss per share:
Basic and diluted	$	(0.01	)	$	(0.13	)
Shares used in per share computations:
Weighted average shares outstanding – basic and diluted	18,518			19,322
Dividends declared per common share	$	0.05		$	—
Net loss	$	(148	)	$	(2,419	)
Other comprehensive loss:
Unrealized loss on marketable securities	(18		)	(40		)
Total other comprehensive loss	(18		)	(40		)
Comprehensive loss	$	(166	)	$	(2,459	)

See accompanying notes to unaudited condensed consolidated financial statements

4

DIGIRAD CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except share data)	March 31, 2014			December 31, 2013
Assets
Current assets:
Cash and cash equivalents	$	9,549		$	18,744
Securities available-for-sale	9,871			7,673
Accounts receivable, net	7,308			5,430
Inventories, net	3,755			3,881
Other current assets	697			697
Restricted cash	477			244
Total current assets	31,657			36,669
Property and equipment, net	4,514			4,153
Intangible assets, net	2,867			353
Goodwill	1,459			184
Other assets	62			92
Total assets	$	40,559		$	41,451
Liabilities and stockholders’ equity
Accounts payable	$	1,293		$	611
Accrued compensation	2,622			3,472
Accrued warranty	148			137
Deferred revenue	1,381			1,631
Other accrued liabilities	2,103			1,774
Total current liabilities	7,547			7,625
Other liabilities	667			440
Total liabilities	8,214			8,065
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	—			—
Common stock, $0.0001 par value: 80,000,000 shares authorized; 18,504,279shares issued and outstanding (net of treasury shares) at March 31, 2014 and December 31, 2013	2			2
Treasury stock, at cost; 2,588,484 shares at March 31, 2014 and December 31, 2013	(5,728		)	(5,728		)
Additional paid-in capital	156,093			156,968
Accumulated other comprehensive loss	(20		)	(2		)
Accumulated deficit	(118,002		)	(117,854		)
Total stockholders’ equity	32,345			33,386
Total liabilities and stockholders’ equity	$	40,559		$	41,451

See accompanying notes to unaudited condensed consolidated financial statements

5

DIGIRAD CORPORATION

CONDENSED CONSOLIDATED STATEMENTS

OF CASH FLOWS

(Unaudited)

	Three Months Ended March 31,
(in thousands)	2014			2013
Operating activities
Net loss	$	(148	)	$	(2,419	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	387			427
Amortization of intangible assets	66			66
Provision for bad debt	21			11
Stock-based compensation	50			121
Gain on sale of assets	5			—
Amortization of premiums on investments	51			46
Changes in operating assets and liabilities:
Accounts receivable	(1,699		)	500
Inventories	293			130
Other assets	70			(89		)
Accounts payable	449			352
Accrued compensation	(1,019		)	252
Deferred revenue	(250		)	(369		)
Other liabilities	168			(197		)
Restricted cash	(233		)	—
Net cash used in operating activities	(1,789		)	(1,169		)
Investing activities
Purchases of property and equipment	(571		)	(189		)
Purchases of securities available-for-sale	(2,617		)	(4,679		)
Sales and maturities of securities available-for-sale	350			2,050
Net cash paid for acquisition	(3,470		)	—
Net cash used in investing activities	(6,308		)	(2,818		)
Financing activities
Issuances of common stock	—			29
Repurchases of common stock	—			(20		)
Dividend paid	(925		)	—
Repayment of long-term debt	(131		)	—
Repayment of obligations under capital leases	(42		)	—
Net cash provided by (used in) financing activities	(1,098		)	9
Net decrease in cash and cash equivalents	(9,195		)	(3,978		)
Cash and cash equivalents at beginning of period	18,744			19,514
Cash and cash equivalents at end of period	$	9,549		$	15,536

See accompanying notes to unaudited condensed consolidated financial statements

6

DIGIRAD CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. The Company

Digirad Corporation (“Digirad”), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound imaging services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals and imaging centers through our Diagnostic Services reportable segment. Digirad also sells medical diagnostic imaging systems, including solid-state gamma cameras, for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold, through our Diagnostic Imaging reportable segment. These two reportable segments, Diagnostic Services and Diagnostic Imaging, are collectively referred to herein as the “Company.”

The accompanying condensed consolidated financial statements include the operations of both segments. Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States.

Basis of Presentation

The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2013, filed with the SEC on Form 10-K on March 20, 2014 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. In addition certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates.

The financial results for the three months ended March 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014. See Note 3 for more information related to the acquisition of Telerhythmics, LLC.

Note 2. Basic and Diluted Net Loss Per Share

For the three months ended March 31, 2014 and 2013, basic net loss per common share is computed by dividing net loss by the weighted average number of common shares and vested restricted stock units outstanding during the period. Diluted net loss per common share is calculated to give effect of all dilutive securities, if applicable, using the treasury stock method.

The following table sets forth the reconciliation of shares used to compute basic and diluted net loss per share for the periods indicated:

	Three Months Ended March 31,
(shares in thousands)	2014	2013
Weighted average shares outstanding - basic	18,518	19,322
Dilutive potential common stock outstanding:
Stock options	—	—
Restricted stock units	—	—
Weighted average shares outstanding - diluted	18,518	19,322

The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net loss per share because their effect was anti-dilutive:

	Three Months Ended March 31,
(shares in thousands)	2014	2013
Stock options	373	303
Restricted stock units	—	16
Total	373	319

7

Note 3. Acquisition of Telerhythmics, LLC

On March 13, 2014, we entered into a membership interest purchase agreement (the “Purchase Agreement”) to acquire 100% of the membership interest of Telerhythmics, LLC ("Telerhythmics"), a provider of 24 hour cardiac monitoring services. Telerhythmics and Digirad each have a very similar customer base, yet with only minor overlaps in current customers. We believe this similar customer base will allow us to leverage each company’s strengths to grow sales and also diversify Digirad service offerings.

Under the terms of the Purchase Agreement, we paid to the sellers of the membership interest (the "Sellers") aggregate estimated up front consideration of $3.52 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (“EBITDA”) milestones. The Sellers will receive fifty percent (50%) of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are as follows:

• $415,000 of EBITDA for the period from the closing date through December 31, 2014,

• $825,000 of EBITDA for the period from January 1, 2015 through December 31, 2015; and

• $825,000 of EBITDA for the period from January 1, 2016 through December 31, 2016.

At March 31, 2014, we have estimated the fair value of the contingent earn-out opportunity to be $220,000. The earn-out opportunity is estimated based on expected performance of the business over the period from the acquisition date through December 31, 2016, utilizing an income approach. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes.

The Purchase Agreement is also subject to a post-closing purchase price adjustment based on the final working capital balance, as defined in the Purchase Agreement.    

The following table summarizes the purchase price allocation recognized as of the close date of March 13, 2014:

	March 13, 2014
Assets
Current assets:
Accounts receivable, net	$	200
Other current assets	41
Total current assets	241
Property and equipment, net	290
Intangible assets, net	2,580
Goodwill	1,275
Total assets	$	4,386
Accounts payable	$	36
Accrued compensation	169
Other accrued liabilities	356
Current portion of long-term debt	131
Total current liabilities	692
Other liabilities	174
Total liabilities	$	866

The long-term debt was subsequently paid in full on March 28, 2014.

The goodwill recognized as part of the transaction primarily represents synergies between Digirad and Telerhythmics that were not separately identified as part of the acquisition valuation process. Telerhythmics activities are considered their own operating segment, which is aggregated into our Diagnostic Services reportable segment (formerly Digirad Imaging Solutions). The resulting goodwill from the acquisition is expected to be deductible for Federal and state tax reporting purposes.

As of March 31, 2014, the final working capital adjustment has not been completed, and therefore the accounting for the acquisition is incomplete. We have estimated the working capital adjustment at March 13, 2014 at approximately $49,000 due to

8

the Sellers, which is included in the estimated consideration above. It is reasonably possible this estimated working capital adjustment could change based on the final agreed upon amount pursuant to the Purchase Agreement. Any adjustment to this amount will affect the purchase consideration, and therefore the allocation of the purchase price, with the majority of any such adjustment likely affecting the recorded goodwill amount. We anticipate closing the measurement period by June 30, 2014.

The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.

	Three Months Ended March 31, 2014						Three Months Ended March 31, 2013
	Digirad		Telerhythmics		Proforma		Digirad			Telerhythmics			Proforma
Revenues	$	12,742	$	1,410	$	14,152	$	11,546		$	1,413		$	12,959
Net income (loss)	$	19	$	7	$	26	$	(2,419	)	$	(115	)	$	(2,534	)

Included within our consolidated operating results for the period ending March 31, 2014 are Telerhythmics operations for the period March 14, 2014 through March 31, 2014 as follows:

	March 14, 2014 - March 31, 2014
Revenues	$	255
Net loss	$	(167	)

Included within the results for Telerhythmics is approximately $155,000 of transaction costs related to the acquisition. These costs are classified as general and administrative expenses in the consolidated statements of comprehensive loss.

Note 4. Inventories

Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.

(in thousands)	March 31, 2014			December 31, 2013
Raw materials	$	2,407		$	2,619
Work-in-process	3,048			3,189
Finished goods	669			616
	6,124			6,424
Less reserve for excess and obsolete inventories	(2,369		)	(2,543		)
Inventories, net	$	3,755		$	3,881

Note 5. Property and Equipment

(in thousands)	March 31, 2014			December 31, 2013
Machinery and equipment	$	23,216		$	22,596
Computer hardware and software	2,520			2,497
Leasehold improvements	900			861
	26,636			25,954
Accumulated depreciation	(22,122		)	(21,801		)
Property and equipment, net	$	4,514		$	4,153

9

Note 6. Intangibles and Goodwill

	March 31, 2014
	Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
Intangible assets with infinite useful lives:
Goodwill (2)	Indefinite	$	1,459	$	—		$	1,459
Intangible assets with finite useful lives:
Customer relationships (2)	8.3	$	4,850	$	(2,682	)	$	2,168
Trademarks (2)	9.0	600		(3		)	597
Patents	4.8	141		(108		)	33
Covenants not to compete (2)	5.0	70		(1		)	69
Total intangible assets, net		$	5,661	$	(2,794	)	$	2,867

	December 31, 2013
	Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net
Intangible assets with infinite useful lives:
Goodwill	Indefinite	$	184	$	—		$	184
Intangible assets with finite useful lives:
Customer relationships	3.5	$	2,940	$	(2,622	)	$	318
Patents	4.9	141		(106		)	35
Total intangible assets, net		$	3,081	$	(2,728	)	$	353

(1) Amortization expense for intangible assets, net was $0.1 million for the three months ended March 31, 2014 and 2013. Estimated amortization expense for intangible assets for the remainder of 2014 is $0.3 million, for 2015 is $0.4 million, for 2016 is $0.4 million, for 2017 is $0.4 million, for 2018 is $0.3 million, for 2019 and thereafter is $1.2 million.

(2) As a result of our acquisition of Telerhythmics, LLC on March 13, 2014, we recored certain intangible assets. See Note 3.

Note 7. Restructuring Charges

Diagnostic Imaging restructuring initiative

On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs and focus on maximizing cash flow from our Diagnostic Services business (the "Diagnostic Imaging restructuring initiative"). The Diagnostic Imaging restructuring initiative included a reduction in force. In addition, as part of the Diagnostic Imaging restructuring initiative, we entered into an agreement in September 2013 with a third party to outsource the majority of the manufacturing associated with our cameras. As a result of the Diagnostic Imaging restructuring initiative, we incurred a total of $1.8 million in restructuring charges, the majority of which were incurred during fiscal year 2013. Included in the total Diagnostic Imaging restructuring initiative charges are $1.6 million of employee related costs, with the remaining costs consisting of contract termination costs and other related costs. All restructuring efforts associated with this initiative were substantially complete as of March 31, 2014.

The following table includes information regarding our Diagnostic Imaging restructuring initiative:

(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
Total Diagnostic Imaging restructuring initiative	$	489	$	27	$	396	$	120

All accrued Diagnostic Imaging restructuring charges at March 31, 2014 are included in the accrued compensation line item in the unaudited condensed consolidated balance sheets. All the Diagnostic Imaging restructuring charges are included in the Diagnostic Imaging segment.

Facilities restructuring initiative

10

On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the "Facilities restructuring initiative"). This action was undertaken as the facility has excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations.

As a result of the Facilities restructuring initiative, we estimate that we will incur in total approximately $0.5 million to $0.7 million in restructuring charges, which we anticipate to be incurred in the first three quarters of fiscal year 2014. The estimated charges are comprised of lease termination, moving and other related costs. Through March 31, 2014, we have incurred approximately $0.4 million of charges associated with the Facilities restructuring initiative, consisting primarily of lease termination costs. Restructuring liabilities and associated charges are measured at fair value as incurred.

The following table includes information regarding our Facilities restructuring initiative:

(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
Total Facilities restructuring initiative	$	—	$	414	$	256	$	158

All accrued Facilities restructuring charges at March 31, 2014 are included in the other accrued liabilities line item in the unaudited condensed consolidated balance sheets. All the Facilities restructuring charges for the period ended March 31, 2014 are included in the Diagnostic Imaging segment.

Note 8. Financial Instruments

Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2014 and December 31, 2013.

	Fair Value as of March 31, 2014
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Corporate debt securities	$	—	$	9,871	$	—	$	9,871
Liabilities:
Acquisition related contingent consideration	$	—	$	—	$	220	$	220

	Fair Value as of December 31, 2013
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Corporate debt securities	$	—	$	7,673	$	—	$	7,673

The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. We did not reclassify any investments between levels in the fair value hierarchy during the three months ended March 31, 2014.

The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014 (See Note 3).  We will reassess the fair value of the contingent consideration to be settled in cash related to our acquisition of Telerhythmics on a quarterly basis using the income approach, which is a Level 3 measurement. Significant assumptions used in the measurement include probabilities of achieving the EBITDA milestones.

Securities Available for Sale

Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale

11

security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the three months ended March 31, 2014 and 2013.

The following table sets forth the composition of securities available-for-sale as of March 31, 2014 and December 31, 2013.

	Maturity in Years	Amortized Cost		Unrealized					Fair Value
As of March 31, 2014 (in thousands)				Gains		Losses
Corporate debt securities	3 or less	$	9,891	$	6	$	(26	)	$	9,871
	Maturity in Years	Amortized Cost		Unrealized					Fair Value
As of December 31, 2013 (in thousands)				Gains		Losses
Corporate debt securities	3 or less	$	7,675	$	—	$	(2	)	$	7,673

Note 9. Commitments and Contingencies

Leases

We currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from April 1, 2014 through February 28, 2021. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other liabilities. Rent expense was approximately $0.4 million for the three months ended March 31, 2014 and 2013.

As of March 31, 2014, we financed certain information technology and medical equipment and vehicles under capital leases. These obligations are secured by the specific equipment financed under each lease and will be repaid monthly over the remaining lease terms through March 31, 2018.

The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of March 31, 2014 are as follows (in thousands):

	Operating Leases		Capital Leases
2014	$	662	$	161
2015	883		214
2016	522		140
2017	258		24
2018	215		3
2019	221		—
Thereafter	266		—
Total minimum lease payments	$	3,027	$	542

Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Note 10. Income Taxes

As of December 31, 2013, we had unrecognized tax benefits of approximately $1.6 million. Included in the unrecognized tax benefits were $1.3 million of tax benefits that, if recognized, would have a favorable impact on our annual effective tax rate, subject to the valuation allowance. We do not expect our unrecognized tax benefits to change significantly over the next 12 months.

We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2008; however, our net operating loss and research credit

12

carry-forwards arising prior to that year are subject to adjustment. It is our policy to recognize interest expense and penalties related to income tax matters as a component of income tax expense.

Note 11. Segments

Our reportable segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.

On March 13, 2014, we acquired all the outstanding membership interest of Telerhythmics, LLC (See Note 3). As part of the acquisition, we evaluated Telerhythmics' business operations, both on a quantitative and qualitative basis, and determined its business operations appropriately met the criteria to be aggregated with our Diagnostic Services business in accordance with the authoritative accounting guidance for segment reporting. The Diagnostic Services reportable segment was renamed in conjunction with the acquisition from Digirad Imaging Solutions.

The financial results below for the three months ended March 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014.

	Three Months Ended March 31,
(in thousands)	2014			2013
Gross profit by segment:
Diagnostic Services	$	2,021		$	2,114
Diagnostic Imaging	1,421			703
Condensed consolidated gross profit	$	3,442		$	2,817
Income (loss) from operations by segment:
Diagnostic Services	$	(333	)	$	(144	)
Diagnostic Imaging (1)	178			(2,265		)
Condensed consolidated loss from operations	$	(155	)	$	(2,409	)
Depreciation and amortization:
Diagnostic Services	$	375		$	392
Diagnostic Imaging	78			101
Condensed consolidated depreciation and amortization	$	453		$	493

(in thousands)	As of March 31, 2014		As of December 31, 2013
Identifiable assets by segment:
Diagnostic Services	$	15,172	$	11,874
Diagnostic Imaging	25,387		29,577
Condensed Consolidated assets	$	40,559	$	41,451

⁽¹⁾Included in the Diagnostic Imaging income (loss) from operations for the three months ended March 31, 2014 and 2013, are approximately $0.4 million and $1.0 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7).

Note 12. Subsequent Events

On May 1, 2014, the Company’s Board of Directors declared a cash dividend of $0.05 per share payable on May 27, 2014 to shareholders of record on May 13, 2014.

13

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition and results of operations (“MD&A”), contains forward-looking statements that involve risks and uncertainties. Please see “Important Information Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions that may cause our actual results to differ materially from those discussed in the forward-looking statements. This discussion should be read in conjunction with our unaudited condensed consolidated financial statements and related notes thereto and the other disclosures contained elsewhere in this Quarterly Report on Form 10-Q, and the audited consolidated financial statements and related notes thereto for the fiscal year ended December 31, 2013, which were included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 20, 2014.

The results of operations for the periods reflected herein are not necessarily indicative of results that may be expected for future periods.

Overview

We are one of the largest national providers of in-office nuclear cardiology imaging and ultrasound imaging services, and also provide cardiac event monitoring services. These services are provided to physician practices, hospitals and imaging centers through our Diagnostic Services reportable segment. We also sell medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provide service on the products we sell through our Diagnostic Imaging reportable segment. We designed and commercialized the first solid-state nuclear gamma camera for the detection of cardiovascular disease and other medical conditions. Our nuclear cameras fit easily into floor spaces as small as seven feet by eight feet and facilitate the delivery of nuclear medicine procedures in a physician’s office, an outpatient hospital setting or within multiple departments of a hospital, (e.g., emergency and operating rooms).

Through Diagnostic Services, we offer a comprehensive diagnostic services program as an alternative to purchasing a gamma camera or ultrasound equipment for physicians who wish to perform nuclear imaging, echocardiography, vascular ultrasound, or any combination of these procedures in their offices by utilizing our imaging systems, certified personnel and other support required to perform imaging in the physician’s office. We also provide cardiac event monitoring services on an outsourced basis to these same customers as a solution to diagnose and monitor the cardiac condition of patients. Our cardiac event monitoring services provide our customers with flexibility and a high level of customer service, while saving them the capital investment of owning the underlying equipment and the logistics costs of delivering that service. Our Diagnostic Services are primarily provided to cardiologists, internal medicine physicians, family practice doctors and hospitals. Our nuclear and ultrasound imaging customers enter into contracts for our services delivered on a per-day basis. Our typical contract provides service coverage ranging from once per month to five times per week. For our cardiac event monitoring services, we enter into agreements with insurance providers for agreed upon rates for our services, but our services are provided directly to patients or the underlying physician as part of their care for the patient. The flexibility of our products and services allows physicians more control over the diagnosis and treatment of their patients in their offices and to retain revenue from procedures they would otherwise refer elsewhere.

We experience some seasonality in our Diagnostic Services business related to vacations, holidays and inclement weather. We may experience significant market changes due to fluctuations in reimbursements to our physician customers and the uncertainty with healthcare legislation. These market changes may require further adjustments to our business model in order for our physician customers and us to maintain a viable economic model.

Our Diagnostic Imaging segment revenue results primarily from selling solid-state gamma cameras and camera maintenance contracts. We sell our imaging systems to physician offices and hospitals primarily in the United States.

For many years since our Initial Public Offering in 2004, we have focused significant efforts on research and development activities to develop and further enhance our nuclear imaging cameras, primarily for alternative uses within the health care environment. These efforts, along with a fixed infrastructure that was sized for a much higher volume of manufacturing and sales of our nuclear imaging cameras than we have experienced, has resulted in several years of financial losses. On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs and improve profitability. With this restructuring, we are focusing our efforts on growing our Diagnostic Services business, while at the same time continuing to sell and service our cameras, but at a more profitable level, and with a vastly modified infrastructure. We believe that our cameras have underlying technology and related patents that make them relevant for many years into the future, negating the need for a fixed cost research and development infrastructure.

14

Results of Operations

The following tables set forth our results from operations for the three months ended March 31, 2014 and 2013:

	Three Months Ended March 31,
	2014			Percent of 2014 Revenues		2013			Percent of 2013 Revenues		Change from Prior Year
(in thousands)											Dollars			Percent
Revenues:
Diagnostic Services	$	9,555		73.5	%	$	8,939		77.4	%	$	616		6.9	%
Diagnostic Imaging	3,442			26.5	%	2,607			22.6	%	835			32.0	%
Total revenues	12,997			100	%	11,546			100	%	1,451			12.6	%
Cost of revenues:
Diagnostic Services	7,534			58.0	%	6,825			59.1	%	709			10.4	%
Diagnostic Imaging	2,021			15.5	%	1,904			16.5	%	117			6.1	%
Total cost of revenues	9,555			73.5	%	8,729			75.6	%	826			9.5	%
Gross profit	3,442			26.5	%	2,817			24.4	%	625			22.2	%
Diagnostic Services gross profit percentage	21.2		%			23.6		%						(2.4	)%
Diagnostic Imaging gross profit percentage	41.3		%			27.0		%						14.3	%
Operating expenses:
Research and development	—			—	%	818			7.1	%	(818		)	(100.0	)%
Marketing and sales	1,095			8.4	%	1,236			10.7	%	(141		)	(11.4	)%
General and administrative	1,995			15.3	%	2,102			18.2	%	(107		)	(5.1	)%
Amortization of intangible assets	66			0.5	%	66			0.6	%	—			—	%
Restructuring charges	441			3.4	%	1,004			8.7	%	(563		)	(56.1	)%
Total operating expenses	3,597			27.6	%	5,226			45.3	%	(1,629		)	(31.2	)%
Loss from operations	(155		)	(1.2	)%	(2,409		)	(20.9	)%	2,254			(93.6	)%
Total other income	9			0.1	%	22			0.2	%	(13		)	(59.1	)%
Loss before income taxes	(146		)	(1.1	)%	(2,387		)	(20.7	)%	2,241			(93.9	)%
Income tax expense	(2		)	—	%	(32		)	(0.3	)%	30			(93.8	)%
Net loss	$	(148	)	(1.1	)%	$	(2,419	)	(21.0	)%	$	2,271		(93.9	)%

Comparison of the Three Months Ended March 31,2014 and 2013

Revenues

Consolidated. Consolidated revenue was $13.0 million for the three months ended March 31, 2014, an increase of $1.5 million, or 12.6%, compared to the prior year period, as a result of increases in revenue in both our Diagnostic Services and Diagnostic Imaging businesses. Increased camera unit sales volume year over year and improved camera unit average selling prices drove increased Diagnostic Imaging revenue. The increased revenue in our Diagnostic Services business was attributable to a greater number of imaging days provided, offset partially by a decrease in the average mobile imaging rate per day. In addition, for the three months ended March 31, 2014, Diagnostic Services benefited from approximately $0.3 million of cardiac event monitoring revenue associated with the acquisition of Telerhythmics. Diagnostic Services revenue accounted for 73.5% of total revenues for the three months ended March 31, 2014, compared to 77.4% for the prior year period. The percentage of consolidated revenue associated with our Diagnostic Services segment was lower for the three months ended March 31, 2014 compared to the same period in the prior year, primarily as a result of the 32.0% increase in Diagnostic Imaging revenue for the three months ended March 31, 2014 compared to the same period in the prior year, while Diagnostic Services revenue increased at a less rapid pace for the three months ended March 31, 2014 compared to the same period in the prior year. We expect our Diagnostic Services revenue to continue to represent the larger percentage of our consolidated revenue, however the percentage will fluctuate quarter by quarter given the significant variability in the timing and volume of camera unit sales.

15

Cost of Revenue and Gross Profit

Consolidated. Consolidated gross profit was $3.4 million for the three months ended March 31, 2014, an increase of $0.6 million, or 22.2%, compared to the prior year quarter. The increase in consolidated gross profit is primarily the result of higher Diagnostic Imaging revenue and improved camera unit average selling prices during the three months ended March 31, 2014, compared to the prior year quarter.

Diagnostic Services. Cost of Diagnostic Services revenue primarily consists of labor, radiopharmaceuticals, equipment depreciation, and other costs associated with providing our services. Cost of Diagnostic Services revenue was $7.5 million for the three months ended March 31, 2014, an increase of $0.7 million, or 10.4%, compared to the prior year quarter, primarily as a result of the increased amount of revenue and associated imaging days provided as well as increased labor costs. Diagnostic Services gross profit was $2.0 million for the three months ended March 31, 2014, a decrease of $0.1 million, or 4.4%, from gross profit of $2.1 million for the prior year quarter. Diagnostic Services gross profit as a percentage of Diagnostic Services revenue decreased to 21.2% for the three months ended March 31, 2014 from 23.6% for the prior year quarter. The decrease in gross profit and gross profit as a percentage of Diagnostic Services revenue was primarily attributable to adverse weather conditions on the east coast of the United States, which adversely affected the utilization of our labor pool. In addition, our radiopharmaceutical costs per imaging procedure increased period over period due to unfavorable changes in the mix of radiopharmaceutical utilized.

Diagnostic Imaging. Cost of Diagnostic Imaging revenue primarily consists of materials, labor and overhead costs associated with the manufacturing, warranty and service contracts associated with our products. Cost of Diagnostic Imaging revenue was $2.0 million for the three months ended March 31, 2014, an increase of $0.1 million, or 6.1%, compared to the prior year quarter, which is primarily the result of increased camera unit revenue volume, partially offset by less costs associated with excess inventory reserves period over period. Diagnostic Imaging gross profit was $1.4 million for the three months ended March 31, 2014, an increase of $0.7 million, or 102.1%, compared to the prior year quarter primarily as a result of increased camera unit revenue volume, lower camera manufacturing costs and less cost associated with excess inventory reserves. Diagnostic Imaging gross profit as a percentage of Diagnostic Imaging revenue was 41.3% for the three months ended March 31, 2014, compared to 27.0% for the prior year quarter due to improved average selling prices for cameras, lower camera manufacturing costs and less cost associated with excess inventory reserves.

Operating Expenses

Research and Development. Research and development expenses are the costs associated with the design, development and expansion of our existing technology and consist of salaries, development material costs, facility and overhead costs, consulting fees, and engineering costs. We did not incur research and development expenses during the three months ended March 31, 2014, representing a decrease of $0.8 million, or 100.0%, from the prior year quarter. The decrease is due to our Diagnostic Imaging restructuring initiative, which focuses on our existing camera product offerings rather than continued development of completely new product offerings. We believe our current product line has a technological advantage over competing products and continued relevance well into the future. We expect research and development expense for the remainder of fiscal year 2014 to be minimal, notwithstanding any one-time initiatives. Going forward we plan to primarily utilize outside service providers for research and development services on an as needed basis for updates and enhancements, with the amount of corresponding expenditure fluctuating commensurately quarter by quarter.

Marketing and Sales. Marketing and sales expenses consist primarily of salaries, commissions, travel and marketing costs. Marketing and sales expenses were $1.1 million for the three months ended March 31, 2014, a decrease of $0.1 million, or 11.4%, compared to the prior year quarter, primarily as a result of the Diagnostic Imaging restructuring initiative which introduced an overall reduction in operating expenses including marketing and sales expense. On a go forward basis, we expect marketing and sales expense to generally approximate the level of expense noted in the three months ended March 31, 2014 notwithstanding any one-time initiatives.

General and Administrative. General and administrative expenses consist primarily of salaries and other related costs for finance, human resources, information technology, executive personnel, legal related costs, professional fees, outside services, insurance, and costs related to our board of directors. General and administrative expenses were $2.0 million for the three months ended March 31, 2014, a decrease of $0.1 million, or 5.1%, compared to the prior year quarter primarily as a result of the Diagnostic Imaging restructuring initiative which involved a reduction in spending in various functional areas such as human resources, information technology and finance. The aforementioned decreases in general and administrative expense for the three months ended March 31, 2014 as compared to the prior year quarter, were offset by transaction costs and on going administrative costs associated with the acquisition of Telerhythmics.

Restructuring. On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs, including a reduction in force (the "Diagnostic Imaging restructuring initiative"). A total of $1.8 million of costs have been incurred related to the Diagnostic Imaging restructuring initiative to date, including costs of $27 thousand for the three months ended March 31, 2014 which represents a decrease of $1.0 million compared to the prior year quarter. The Diagnostic Imaging restructuring initiative costs consist primarily of employee related costs.

16

On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the "Facilities restructuring initiative"). This action was undertaken as the facility has excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations. A total of $0.4 million of costs have been incurred related to the Facilities restructuring initiative, with all of the cost occurring in the three months ended March 31, 2014. The Facilities restructuring initiative costs consist primarily of lease termination costs.

Liquidity and Capital Resources

Overview

We used $1.8 million of cash in operating activities during the three months ended March 31, 2014, but withstanding restructuring initiatives, expect to generate positive cash flow from operations on an annual basis in the future. Cash flows from operations generally represent inflows from net income (adjusted for depreciation, amortization and other non-cash items) as well as the net effect of changes in working capital. Cash flows from investing activities primarily represent our investment in capital equipment required to grow our business, as well as acquisition and divestiture activity. Cash flows from financing activities primarily represent outflows related to our share repurchase program and recently initiated dividend payment, offset by the receipt of cash related to the exercise of stock options.

Our principal sources of liquidity are our existing cash and cash equivalents, short-term investments, and cash generated from operations. As of March 31, 2014, we had cash, cash equivalents and securities available-for-sale of $19.4 million. We generally invest our cash reserves in money market funds, U.S. treasury and corporate debt securities.

We require capital principally for capital expenditures, acquisition activity, dividend payments and to finance accounts receivable and inventory, which we manage closely. Our working capital requirements vary from period to period depending on inventory requirements, the timing of deliveries and the payment cycles of our customers. Our capital expenditures consist primarily of nuclear cameras, ultrasound machines, vans, and computer hardware and software. Based upon our current level of expenditures, we believe our current working capital, together with cash flows from operating activities, will be more than adequate to meet our anticipated cash requirements for at least the next 12 months.

Cash Flows

The following table shows cash flow information for the three months ended March 31, 2014 and 2013:

	Three Months Ended March 31,
(in thousands)	2014			2013
Net cash used in operating activities	$	(1,789	)	$	(1,169	)
Net cash used in investing activities	(6,308		)	(2,818		)
Net cash provided by (used in) financing activities	(1,098		)	9

Operating Activities

Net cash used in operating activities increased $0.6 million for the three months ended March 31, 2014 compared to the prior year period. This increase in the use of cash was primarily related to unfavorable overall working capital changes, with an increase in accounts receivable and a decrease in accrued compensation. The decrease in accrued compensation was related to the annual payment of variable incentive compensation as well as Diagnostic Imaging restructuring initiative severance payments. In addition, we had a lease termination payment associated with the Facilities restructuring initiative during the three months ended March 31, 2014.

Investing Activities

Net cash used in investing activities increased $3.5 million for the three months ended March 31, 2014 compared to the prior year period. This increase was primarily attributable to the acquisition of Telerhythmics. See Note 3 to the unaudited condensed consolidated financial statements for further information related to the acquisition of Telerhythmics.

Financing Activities

Net cash used in financing activities increased by $1.1 million for the three months ended March 31, 2014 compared to the prior year period. This increase is attributable to the payment of a cash dividend on common stock during the three months ended March 31, 2014.

17

Off-Balance Sheet Arrangements

As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, or SPEs, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of March 31, 2014, we were not involved in any unconsolidated SPE transactions.

Contractual Obligations

We have made significant changes to our contractual obligations from those disclosed within “Management's Discussion and Analysis of Financial Condition and Results of Operations,” as contained in our Annual Report on Form 10-K filed with the SEC on March 20, 2014. The following table summarizes our contractual obligations as of March 31, 2014 (amounts in thousands):

	Payments Due by Period (1)
Contractual Obligations	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Operating lease obligations	$	3,027	$	662	$	1,405	$	694	$	266
Capital lease obligations(2)	542		161		354		27		—
Total Contractual Obligations	$	3,569	$	823	$	1,759	$	721	$	266

⁽¹⁾ The table excludes $0.2 million of contingent consideration related to the acquisition of Telerhythmics.

⁽²⁾ Capital lease obligations includes related interest obligations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our exposure to market risk due to changes in interest rates relates primarily to the increase or decrease in the value of debt securities in our investment portfolio. Our risk associated with fluctuating interest rates is limited to our investments in interest rate sensitive financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities. A 100 basis point adverse move in interest rates along the entire interest rate yield curve would not materially affect the fair value of our interest sensitive financial instruments. Changes in interest rates over time will increase or decrease our interest income.

ITEM 4. CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities and Exchange Commission Act of 1934 reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Securities and Exchange Commission Rule 13a-15(e) and 15d-15(e), we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

In connection with our acquisition of Telerhythmics, certain areas of internal control over financial reporting changed. These areas are primarily related to integrating corporate functions at Digirad that previously existed at Telerhythmics. The functions and related internal controls that were affected as a result of the acquisition of Telerhythmics are financial reporting, human resources and information technology. Certain control structure items remain in operation at Telerhythmics, primarily related to the processing and billing of revenues, and collection of those revenues. The control structure at Digirad and been modified to appropriately oversee and incorporate these activities into the overall control structure.

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance

18

that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

19

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 7 to the unaudited Condensed Consolidated Financial Statements for a summary of legal proceedings.

ITEM 1A. RISK FACTORS

In evaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q, as well as the risk factors disclosed in Item 1A to Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which we filed with the SEC on March 20, 2014. Beyond what is described below, the risks and uncertainties described in “Item 1A – Risk Factors” of our Annual Report on Form 10-K have not materially changed. Any of the risks discussed in this Quarterly Report on Form 10-Q or any of the risks disclosed in Item 1A to Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations or financial condition.

We may not be able to achieve the anticipated synergies and benefits from business acquisitions, including our recent acquisition of Telerhythmics, LLC.

Part of our ongoing business strategy is to acquire businesses that we believe can complement our current business activities, both financially and strategically. On March 13, 2014, we acquired Telerhythmics, LLC with these synergistic benefits in mind. Acquisitions include many complexities, which can include, but are not limited to risks associated with the acquired business' past activities, loss of customers, regulatory changes that are not anticipated, difficulties in integrating personnel and human resource programs, integrating ERP systems and other infrastructures, and general under performance of the business under Digirad control versus the prior owners. There is no guarantee that our acquisitions will increase the profitability and cash flow of Digirad, and our efforts could cause unforeseen complexities and additional cash outflows, including financial losses.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Effective April 30, 2014, a committee of the Board of Directors of the Company, composed of independent and disinterested directors, granted a waiver request, submitted by Lone Star Value Investors, LP and Jeffrey E. Eberwein, the Company’s Chairman of the Board, pursuant to Section 25(a) of the Company’s Tax Benefit Preservation Plan (the “Benefit Plan”), dated as of May 23, 2013, by and between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent, as amended.  The grant of the waiver request permits Lone Star Value Investors, LP to acquire up to an aggregate of 915,000 additional common shares, for a total aggregate beneficial ownership of 1,830,000 of the Company’s common shares, as determined under the Benefit Plan.

20

ITEM 6. EXHIBITS

Exhibit Number	Description
3.1	Amended and Restated Certificate of Incorporation of Digirad Corporation (Incorporated by reference to the exhibits to the Company’s report on Form 8-K originally filed with the Commission on May 3, 2006, as amended thereafter).
3.2	Amended and Restated Bylaws of Digirad Corporation (Incorporated by reference to the exhibits to the Company's report on Form 8-K originally filed with the Commission on May 9, 2007).
3.3	Certificate of Designation of Rights, Preferences and Privileges of Series B Participating Preferred Stock (Incorporated by reference to the exhibits to the Company's report on Form 8-K originally filed with the Commission on May 24, 2013).
4.1	Form of Specimen Stock Certificate (Incorporated by reference to the exhibits to the Registration Statement on Form S-1 (File No. 333-113760) originally filed with the Commission on March 19, 2004, as amended on May 24, 2004).
4.2	Preferred Stock Rights Agreement, by and between Digirad Corporation and American Stock Transfer and Trust Company, dated November 22, 2005 (Incorporated by reference to the exhibits to the Registration Statement on the Company's report on Form 8-K originally filed with the Commission on November 29, 2005).
4.3	Tax Benefit Preservation Plan by and between Digirad Corporation and American Stock Transfer and Trust Company, dated as of May 23, 2013 (Incorporated by reference to the exhibits to the Company's report on Form 8-K originally filed with the Commission on May 24, 2013).
4.4	Tax Benefit Preservation Plan Amendment, dated November 11, 2013, by and between the Company and American Stock Transfer & Trust Company, LLC (Incorporated by reference to the exhibits to the Company's report on Form 10-K originally filed with the Commission on March 20, 2014).
31.1*	Certification of President and Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended.
31.2*	Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended.
32.1**	Certification of President and Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document***
101.SCH	XBRL Taxonomy Extension Schema***
101.CAL	XBRL Taxonomy Extension Calculation Linkbase***
101.LAB	XBRL Taxonomy Extension Labels Linkbase***
101.PRE	XBRL Taxonomy Extension Presentation Linkbase***
101.DEF	XBRL Taxonomy Extension Definition Linkbase***

_________________ 

* Filed herewith.

** This certification is being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of Digirad Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

*** Furnished, not filed.

21

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		DIGIRAD CORPORATION
Date:	May 2, 2014	By:	/s/    MATTHEW G. MOLCHAN
			Matthew G. Molchan President and Chief Executive Officer (Principal Executive Officer)
Date:	May 2, 2014	By:	/s/     JEFFRY R. KEYES
			Jeffry R. Keyes Chief Financial Officer (Principal Financial and Accounting Officer)

22

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew G. Molchan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Digirad Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

May 2, 2014

/s/    Matthew G. Molchan

Matthew G. Molchan

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffry R. Keyes, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Digirad Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

May 2, 2014

/s/    Jeffry R. Keyes

Jeffry R. Keyes

Chief Financial Officer

(Principal Financial Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the accompanying Quarterly Report on Form 10-Q of Digirad Corporation for the period ended March 31, 2014, I, Matthew G. Molchan, President and Chief Executive Officer of Digirad Corporation, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) such Quarterly Report on Form 10-Q of Digirad Corporation for the period ended March 31, 2014, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in such Quarterly Report on Form 10-Q of Digirad Corporation for the period ended March 31, 2014, fairly presents, in all material respects, the financial condition and results of operations of Digirad Corporation at the dates and for the periods indicated.

This certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

May 2, 2014

/s/     Matthew G. Molchan

Matthew G. Molchan

President and Chief Executive Officer

(Principal Executive Officer)

A signed copy of this written statement required by Section 906 has been provided to Digirad Corporation and will be retained by Digirad Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

EXHIBIT 32.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the accompanying Quarterly Report on Form 10-Q of Digirad Corporation for the period ended March 31, 2014, I, Jeffry R. Keyes, Chief Financial Officer of Digirad Corporation, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) such Quarterly Report on Form 10-Q of Digirad Corporation for the period ended March 31, 2014, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in such Quarterly Report on Form 10-Q of Digirad Corporation for the period ended March 31, 2014, fairly presents, in all material respects, the financial condition and results of operations of Digirad Corporation at the dates and for the periods indicated.

This certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

May 2, 2014

/s/    Jeffry R. Keyes

Jeffry R. Keyes

Chief Financial Officer

(Principal Financial Officer)

A signed copy of this written statement required by Section 906 has been provided to Digirad Corporation and will be retained by Digirad Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Financial Instruments Securities Available for Sale (Details) (3 or less, Corporate debt securities, USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
3 or less | Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Maturities in Years	3 years	3 years
Amortized Cost	$ 9,891	$ 7,675
Unrealized Gains	6	0
Unrealized Losses	(26)	(2)
Fair Value	$ 9,871	$ 7,673

XML

Property and Equipment (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$ 26,636	$ 25,954
Accumulated depreciation	(22,122)	(21,801)
Property and equipment, net	4,514	4,153
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	23,216	22,596
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	2,520	2,497
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, and equipment, gross	$ 900	$ 861

XML

Restructuring Charges (Tables)

3 Months Ended

Mar. 31, 2014

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs

The following table includes information regarding our Facilities restructuring initiative:

(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
Total Facilities restructuring initiative	$	—	$	414	$	256	$	158

The following table includes information regarding our Diagnostic Imaging restructuring initiative:

(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
Total Diagnostic Imaging restructuring initiative	$	489	$	27	$	396	$	120

XML

Segments (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Segment Reporting Information [Line Items]
Gross profit by segment:	$ 3,442		$ 2,817
Income (loss) from operations by segment:	(155)		(2,409)
Depreciation and amortization:	453		493
DIS [Member]
Segment Reporting Information [Line Items]
Gross profit by segment:	2,021		2,114
Income (loss) from operations by segment:	(333)		(144)
Depreciation and amortization:	375		392
Diagnostic Imaging [Member]
Segment Reporting Information [Line Items]
Gross profit by segment:	1,421		703
Income (loss) from operations by segment:	178	[1]	(2,265)
Depreciation and amortization:	$ 78		$ 101

[1] Included in the Diagnostic Imaging income (loss) from operations for the three months ended March 31, 2014 and 2013, are approximately $0.4 million and $1.0 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7)

XML

Restructuring Charges - Facilities restructuring initiative (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 441,000	$ 1,004,000
Facilities Restructuring Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Accrued at December 31, 2013	0
Restructuring and Related Cost, Incurred Cost	400,000
Restructuring charges	414,000
Cash Payments and Other Reductions	256,000
Accrued at March 31, 2014	$ 158,000

XML

Inventories

3 Months Ended

Mar. 31, 2014

Inventory Disclosure [Abstract]

Inventories

Inventories

Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.

(in thousands)	March 31, 2014			December 31, 2013
Raw materials	$	2,407		$	2,619
Work-in-process	3,048			3,189
Finished goods	669			616
	6,124			6,424
Less reserve for excess and obsolete inventories	(2,369		)	(2,543		)
Inventories, net	$	3,755		$	3,881

XML

Segments Asset by Segment Detail (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]
Identifiable assets by segment	$ 40,559		$ 41,451
Restructuring charges	441	1,004
Diagnostic Services
Segment Reporting Information [Line Items]
Identifiable assets by segment	15,172		11,874
Diagnostic Imaging
Segment Reporting Information [Line Items]
Identifiable assets by segment	$ 25,387		$ 29,577

XML

The Company (Details)	3 Months Ended
	Mar. 31, 2014 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	2

XML

Segments (Tables)

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Our reportable segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.

On March 13, 2014, we acquired all the outstanding membership interest of Telerhythmics, LLC (See Note 3). As part of the acquisition, we evaluated Telerhythmics' business operations, both on a quantitative and qualitative basis, and determined its business operations appropriately met the criteria to be aggregated with our Diagnostic Services business in accordance with the authoritative accounting guidance for segment reporting. The Diagnostic Services reportable segment was renamed in conjunction with the acquisition from Digirad Imaging Solutions.

The financial results below for the three months ended March 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014.

	Three Months Ended March 31,
(in thousands)	2014			2013
Gross profit by segment:
Diagnostic Services	$	2,021		$	2,114
Diagnostic Imaging	1,421			703
Condensed consolidated gross profit	$	3,442		$	2,817
Income (loss) from operations by segment:
Diagnostic Services	$	(333	)	$	(144	)
Diagnostic Imaging (1)	178			(2,265		)
Condensed consolidated loss from operations	$	(155	)	$	(2,409	)
Depreciation and amortization:
Diagnostic Services	$	375		$	392
Diagnostic Imaging	78			101
Condensed consolidated depreciation and amortization	$	453		$	493

Reconciliation of Assets from Segment to Consolidated

(in thousands)	As of March 31, 2014		As of December 31, 2013
Identifiable assets by segment:
Diagnostic Services	$	15,172	$	11,874
Diagnostic Imaging	25,387		29,577
Condensed Consolidated assets	$	40,559	$	41,451

⁽¹⁾Included in the Diagnostic Imaging income (loss) from operations for the three months ended March 31, 2014 and 2013, are approximately $0.4 million and $1.0 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7)

XML

Subsequent Event Dividend (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	May 01, 2014 Subsequent event
Subsequent Event [Line Items]
Dividends declared per common share	$ 0.05	$ 0.00	$ 0.05

XML

Basic and Diluted Net Income per Share (Details) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share, Basic and Diluted [Abstract]
Weighted average shares outstanding – basic	18,518	19,322
Dilutive potential common stock outstanding:
Stock options	0	0
Restricted stock units	0	0
Weighted average shares outstanding – diluted	18,518	19,322
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	373	319
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	373	303
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	16

XML

Acquisition of Telerhythmics (Details) (USD $)	1 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 13, 2014
Business Acquisition, Contingent Consideration [Line Items]
Business Acquisition, Expected Working Capital Adjustment				$ 49,000
Business Acquisition, Percentage of Voting Interests Acquired				100.00%
Business Acquisition, Cost of Acquired Entity, Cash Paid	3,520,000	3,520,000
Business Acquisition, Contingent Consideration, Potential Cash Payment	220,000	220,000		501,000
Percentage Of EBITDA To Be Received	50.00%
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	400,000	400,000
Accounts receivable, net				200,000
Other current assets				41,000
Total current assets				241,000
Property and equipment, net				290,000
Intangible assets, net				2,580,000
Goodwill				1,275,000
Total assets				4,386,000
Accounts payable				36,000
Current portion of long-term debt				131,000
Total current liabilities				692,000
Other liabilities				174,000
Total liabilities				866,000
Gross Profit		3,442,000	2,817,000
Operating Expenses		3,597,000	5,226,000
Income Tax Expense (Benefit)		2,000	32,000
Revenues		14,152,000	12,959,000
Net income (loss)		26,000	(2,534,000)
Revenues	255,000
Net loss	(167,000)	(148,000)	(2,419,000)
Business Acquisition, Cost of Acquired Entity, Transaction Costs	155,000	155,000
Year one [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Acquisition, Contingent Consideration, Potential Cash Payment				415,000
Year two [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Acquisition, Contingent Consideration, Potential Cash Payment				825,000
Year three [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Acquisition, Contingent Consideration, Potential Cash Payment				825,000
accrued compensation [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities				169,000
other accrued liabilities [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities				356,000
Telerhythmics [Member]
Business Acquisition, Contingent Consideration [Line Items]
Revenues		1,410,000	1,413,000
Net income (loss)		7,000	(115,000)
digirad [Member]
Business Acquisition, Contingent Consideration [Line Items]
Revenues		12,742,000	11,546,000
Net income (loss)		$ 19,000	$ (2,419,000)

XML

Acquisition of Telerhythmics (Notes)

3 Months Ended

Mar. 31, 2014

Business Combinations [Abstract]

Acquisition of Telerhythmics, LLC

Acquisition of Telerhythmics, LLC

On March 13, 2014, we entered into a membership interest purchase agreement (the “Purchase Agreement”) to acquire 100% of the membership interest of Telerhythmics, LLC ("Telerhythmics"), a provider of 24 hour cardiac monitoring services. Telerhythmics and Digirad each have a very similar customer base, yet with only minor overlaps in current customers. We believe this similar customer base will allow us to leverage each company’s strengths to grow sales and also diversify Digirad service offerings.

Under the terms of the Purchase Agreement, we paid to the sellers of the membership interest (the "Sellers") aggregate estimated up front consideration of $3.52 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (“EBITDA”) milestones. The Sellers will receive fifty percent (50%) of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are as follows:

• $415,000 of EBITDA for the period from the closing date through December 31, 2014,

• $825,000 of EBITDA for the period from January 1, 2015 through December 31, 2015; and

• $825,000 of EBITDA for the period from January 1, 2016 through December 31, 2016.

At March 31, 2014, we have estimated the fair value of the contingent earn-out opportunity to be $220,000. The earn-out opportunity is estimated based on expected performance of the business over the period from the acquisition date through December 31, 2016, utilizing an income approach. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes.

The Purchase Agreement is also subject to a post-closing purchase price adjustment based on the final working capital balance, as defined in the Purchase Agreement.    

The following table summarizes the purchase price allocation recognized as of the close date of March 13, 2014:

	March 13, 2014
Assets
Current assets:
Accounts receivable, net	$	200
Other current assets	41
Total current assets	241
Property and equipment, net	290
Intangible assets, net	2,580
Goodwill	1,275
Total assets	$	4,386
Accounts payable	$	36
Accrued compensation	169
Other accrued liabilities	356
Current portion of long-term debt	131
Total current liabilities	692
Other liabilities	174
Total liabilities	$	866

The long-term debt was subsequently paid in full on March 28, 2014.

The goodwill recognized as part of the transaction primarily represents synergies between Digirad and Telerhythmics that were not separately identified as part of the acquisition valuation process. Telerhythmics activities are considered their own operating segment, which is aggregated into our Diagnostic Services reportable segment (formerly Digirad Imaging Solutions). The resulting goodwill from the acquisition is expected to be deductible for Federal and state tax reporting purposes.

As of March 31, 2014, the final working capital adjustment has not been completed, and therefore the accounting for the acquisition is incomplete. We have estimated the working capital adjustment at March 13, 2014 at approximately $49,000 due to the Sellers, which is included in the estimated consideration above. It is reasonably possible this estimated working capital adjustment could change based on the final agreed upon amount pursuant to the Purchase Agreement. Any adjustment to this amount will affect the purchase consideration, and therefore the allocation of the purchase price, with the majority of any such adjustment likely affecting the recorded goodwill amount. We anticipate closing the measurement period by June 30, 2014.

The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.

	Three Months Ended March 31, 2014						Three Months Ended March 31, 2013
	Digirad		Telerhythmics		Proforma		Digirad			Telerhythmics			Proforma
Revenues	$	12,742	$	1,410	$	14,152	$	11,546		$	1,413		$	12,959
Net income (loss)	$	19	$	7	$	26	$	(2,419	)	$	(115	)	$	(2,534	)

Included within our consolidated operating results for the period ending March 31, 2014 are Telerhythmics operations for the period March 14, 2014 through March 31, 2014 as follows:

	March 14, 2014 - March 31, 2014
Revenues	$	255
Net loss	$	(167	)

Included within the results for Telerhythmics is approximately $155,000 of transaction costs related to the acquisition. These costs are classified as general and administrative expenses in the consolidated statements of comprehensive loss.

XML

Inventories (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Raw materials	$ 2,407	$ 2,619
Work-in-process	3,048	3,189
Finished goods	669	616
Inventory, gross	6,124	6,424
Less reserve for excess and obsolete inventories	(2,369)	(2,543)
Inventories, net	$ 3,755	$ 3,881

XML

Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 400,000
2014	662,000
2015	883,000
2016	522,000
2017	258,000
2018	215,000
2019	221,000
Thereafter	266,000
Total minimum lease payments	3,027,000
2014	161,000
2015	214,000
2016	140,000
2017	24,000
2018	3,000
2019	0
Thereafter	0
Total minimum lease payments	$ 542,000

XML

Condensed Consolidated Statements Of Comprehensive Income (Loss) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:
Diagnostic Services	$ 9,555	$ 8,939
Diagnostic Imaging	3,442	2,607
Total revenues	12,997	11,546
Cost of revenues:
Diagnostic Services	7,534	6,825
Diagnostic Imaging	2,021	1,904
Total cost of revenues	9,555	8,729
Gross profit	3,442	2,817
Operating expenses:
Research and development	0	818
Marketing and sales	1,095	1,236
General and administrative	1,995	2,102
Amortization of intangible assets	66	66
Restructuring charges	441	1,004
Total operating expenses	3,597	5,226
Loss from operations	(155)	(2,409)
Other income (expense):
Interest and other income, net	17	22
Interest expense	(8)	0
Total other income	9	22
Loss before income taxes	(146)	(2,387)
Income tax expense	(2)	(32)
Net loss	(148)	(2,419)
Net loss per share - Basic and diluted	$ (0.01)	$ (0.13)
Weighted average shares outstanding – basic and diluted	18,518	19,322
Dividends declared per common share	$ 0.05	$ 0.00
Other comprehensive loss:
Unrealized loss on marketable securities	(18)	(40)
Total other comprehensive loss	(18)	(40)
Comprehensive loss	$ (166)	$ (2,459)

XML

The Company

3 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

The Company

Digirad Corporation (“Digirad”), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound imaging services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals and imaging centers through our Diagnostic Services reportable segment. Digirad also sells medical diagnostic imaging systems, including solid-state gamma cameras, for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold, through our Diagnostic Imaging reportable segment. These two reportable segments, Diagnostic Services and Diagnostic Imaging, are collectively referred to herein as the “Company.”

The accompanying condensed consolidated financial statements include the operations of both segments. Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States.

Basis of Presentation

The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2013, filed with the SEC on Form 10-K on March 20, 2014 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. In addition certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates.

The financial results for the three months ended March 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014. See Note 3 for more information related to the acquisition of Telerhythmics, LLC.

XML

Restructuring Charges - Narrative (Details) (USD $)	3 Months Ended			15 Months Ended		3 Months Ended			3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014 Diagnostic Imaging Initiative [Member]	Mar. 31, 2014 Diagnostic Imaging Initiative [Member]	Mar. 31, 2014 Diagnostic Imaging Initiative [Member] Employee Severance [Member]	Mar. 31, 2014 Facilities Restructuring Initiative [Member]	Jan. 24, 2014 Facilities Restructuring Initiative [Member] sqft	Jan. 23, 2014 Facilities Restructuring Initiative [Member] sqft	Mar. 31, 2014 Facilities Restructuring Initiative [Member] Minimum [Member]	Mar. 31, 2014 Facilities Restructuring Initiative [Member] Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Area of Real Estate Property							47,000	21,300
Restructuring and Related Cost, Expected Cost									$ 500,000	$ 700,000
Estimated employee related restructuring charges				1,800,000	1,600,000	400,000
Restructuring charges	$ 441,000	$ 1,004,000	$ 27,000			$ 414,000

XML

Inventories (Tables)

3 Months Ended

Mar. 31, 2014

Inventory Disclosure [Abstract]

Schedule of Inventory

Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.

(in thousands)	March 31, 2014			December 31, 2013
Raw materials	$	2,407		$	2,619
Work-in-process	3,048			3,189
Finished goods	669			616
	6,124			6,424
Less reserve for excess and obsolete inventories	(2,369		)	(2,543		)
Inventories, net	$	3,755		$	3,881

XML

Restructuring Charges - Diagnostic Imaging Restructuring Initiative (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Restructuring Reserve [Roll Forward]
Accrued Costs	$ 441	$ 1,004
Diagnostic Imaging Initiative [Member]
Restructuring Reserve [Roll Forward]
Accrued at December 31, 2013	489
Accrued Costs	27
Cash Payments and Other Reductions	396
Accrued at March 31, 2014	$ 120

XML

Intangibles and Goodwill (Tables)

3 Months Ended

Mar. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill

	December 31, 2013
	Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net
Intangible assets with infinite useful lives:
Goodwill	Indefinite	$	184	$	—		$	184
Intangible assets with finite useful lives:
Customer relationships	3.5	$	2,940	$	(2,622	)	$	318
Patents	4.9	141		(106		)	35
Total intangible assets, net		$	3,081	$	(2,728	)	$	353

	March 31, 2014
	Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
Intangible assets with infinite useful lives:
Goodwill (2)	Indefinite	$	1,459	$	—		$	1,459
Intangible assets with finite useful lives:
Customer relationships (2)	8.3	$	4,850	$	(2,682	)	$	2,168
Trademarks (2)	9.0	600		(3		)	597
Patents	4.8	141		(108		)	33
Covenants not to compete (2)	5.0	70		(1		)	69
Total intangible assets, net		$	5,661	$	(2,794	)	$	2,867

XML

Basic And Diluted Net Loss Per Share

3 Months Ended

Mar. 31, 2014

Earnings Per Share, Basic and Diluted [Abstract]

Basic and Diluted Net Income (Loss) Per Share

Basic and Diluted Net Loss Per Share

For the three months ended March 31, 2014 and 2013, basic net loss per common share is computed by dividing net loss by the weighted average number of common shares and vested restricted stock units outstanding during the period. Diluted net loss per common share is calculated to give effect of all dilutive securities, if applicable, using the treasury stock method.

The following table sets forth the reconciliation of shares used to compute basic and diluted net loss per share for the periods indicated:

	Three Months Ended March 31,
(shares in thousands)	2014	2013
Weighted average shares outstanding - basic	18,518	19,322
Dilutive potential common stock outstanding:
Stock options	—	—
Restricted stock units	—	—
Weighted average shares outstanding - diluted	18,518	19,322

The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net loss per share because their effect was anti-dilutive:

	Three Months Ended March 31,
(shares in thousands)	2014	2013
Stock options	373	303
Restricted stock units	—	16
Total	373	319

XML

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 9,549	$ 18,744
Securities available-for-sale	9,871	7,673
Accounts receivable, net	7,308	5,430
Inventories, net	3,755	3,881
Other current assets	697	697
Restricted cash	477	244
Total current assets	31,657	36,669
Property and equipment, net	4,514	4,153
Intangible assets, net	2,867	353
Goodwill	1,459	184
Other assets	62	92
Total assets	40,559	41,451
Liabilities and stockholders' equity
Accounts payable	1,293	611
Accrued compensation	2,622	3,472
Accrued warranty	148	137
Deferred revenue	1,381	1,631
Other accrued liabilities	2,103	1,774
Total current liabilities	7,547	7,625
Other liabilities	667	440
Total liabilities	8,214	8,065
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 18,504,279 shares issued and outstanding (net of treasury shares) at March 31, 2014 and December 31, 2013	2	2
Treasury stock, at cost; 2,588,484 shares at March 31, 2014 and December 31, 2013	(5,728)	(5,728)
Additional paid-in capital	156,093	156,968
Accumulated other comprehensive loss	(20)	(2)
Accumulated deficit	(118,002)	(117,854)
Total stockholders’ equity	32,345	33,386
Total liabilities and stockholders’ equity	$ 40,559	$ 41,451

XML

Subsequent Event (Notes)

3 Months Ended

Mar. 31, 2014

Subsequent Events [Abstract]

Subsequent Event

Subsequent Events

On May 1, 2014, the Company’s Board of Directors declared a cash dividend of $0.05 per share payable on May 27, 2014 to shareholders of record on May 13, 2014.

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 21, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	DIGIRAD CORP
Entity Central Index Key	0000707388
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		18,504,279

XML

Financial Instruments (policies)

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments, Policy

The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers.

Securities Available-for-sale, Policy

Securities Available for Sale

Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss).

XML

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	18,504,279	18,504,279
Common stock, shares outstanding	18,504,279	18,504,279
Treasury stock, shares	2,558,484	2,588,484

XML

Restructuring Charges

3 Months Ended

Mar. 31, 2014

Restructuring and Related Activities [Abstract]

Restructuring Charges

Restructuring Charges

Diagnostic Imaging restructuring initiative

On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs and focus on maximizing cash flow from our Diagnostic Services business (the "Diagnostic Imaging restructuring initiative"). The Diagnostic Imaging restructuring initiative included a reduction in force. In addition, as part of the Diagnostic Imaging restructuring initiative, we entered into an agreement in September 2013 with a third party to outsource the majority of the manufacturing associated with our cameras. As a result of the Diagnostic Imaging restructuring initiative, we incurred a total of $1.8 million in restructuring charges, the majority of which were incurred during fiscal year 2013. Included in the total Diagnostic Imaging restructuring initiative charges are $1.6 million of employee related costs, with the remaining costs consisting of contract termination costs and other related costs. All restructuring efforts associated with this initiative were substantially complete as of March 31, 2014.

The following table includes information regarding our Diagnostic Imaging restructuring initiative:

(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
Total Diagnostic Imaging restructuring initiative	$	489	$	27	$	396	$	120

All accrued Diagnostic Imaging restructuring charges at March 31, 2014 are included in the accrued compensation line item in the unaudited condensed consolidated balance sheets. All the Diagnostic Imaging restructuring charges are included in the Diagnostic Imaging segment.

Facilities restructuring initiative

On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the "Facilities restructuring initiative"). This action was undertaken as the facility has excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations.

As a result of the Facilities restructuring initiative, we estimate that we will incur in total approximately $0.5 million to $0.7 million in restructuring charges, which we anticipate to be incurred in the first three quarters of fiscal year 2014. The estimated charges are comprised of lease termination, moving and other related costs. Through March 31, 2014, we have incurred approximately $0.4 million of charges associated with the Facilities restructuring initiative, consisting primarily of lease termination costs. Restructuring liabilities and associated charges are measured at fair value as incurred.

The following table includes information regarding our Facilities restructuring initiative:

(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
Total Facilities restructuring initiative	$	—	$	414	$	256	$	158

All accrued Facilities restructuring charges at March 31, 2014 are included in the other accrued liabilities line item in the unaudited condensed consolidated balance sheets. All the Facilities restructuring charges for the period ended March 31, 2014 are included in the Diagnostic Imaging segment.

XML

Intangibles and Goodwill (Notes)

3 Months Ended

Mar. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles and Goodwill

	March 31, 2014
	Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
Intangible assets with infinite useful lives:
Goodwill (2)	Indefinite	$	1,459	$	—		$	1,459
Intangible assets with finite useful lives:
Customer relationships (2)	8.3	$	4,850	$	(2,682	)	$	2,168
Trademarks (2)	9.0	600		(3		)	597
Patents	4.8	141		(108		)	33
Covenants not to compete (2)	5.0	70		(1		)	69
Total intangible assets, net		$	5,661	$	(2,794	)	$	2,867

	December 31, 2013
	Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net
Intangible assets with infinite useful lives:
Goodwill	Indefinite	$	184	$	—		$	184
Intangible assets with finite useful lives:
Customer relationships	3.5	$	2,940	$	(2,622	)	$	318
Patents	4.9	141		(106		)	35
Total intangible assets, net		$	3,081	$	(2,728	)	$	353

(1) Amortization expense for intangible assets, net was $0.1 million for the three months ended March 31, 2014 and 2013. Estimated amortization expense for intangible assets for the remainder of 2014 is $0.3 million, for 2015 is $0.4 million, for 2016 is $0.4 million, for 2017 is $0.4 million, for 2018 is $0.3 million, for 2019 and thereafter is $1.2 million.

(2) As a result of our acquisition of Telerhythmics, LLC on March 13, 2014, we recored certain intangible assets. See Note 3.

XML

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2014

Property and Equipment [Abstract]

Property and Equipment

Property and Equipment

(in thousands)	March 31, 2014			December 31, 2013
Machinery and equipment	$	23,216		$	22,596
Computer hardware and software	2,520			2,497
Leasehold improvements	900			861
	26,636			25,954
Accumulated depreciation	(22,122		)	(21,801		)
Property and equipment, net	$	4,514		$	4,153

XML

Commitments And Contingencies Lease (Policies)

3 Months Ended

Mar. 31, 2014

Leases [Abstract]

Leases

We currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from April 1, 2014 through February 28, 2021. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other liabilities.

XML

Income Taxes

3 Months Ended

Mar. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

As of December 31, 2013, we had unrecognized tax benefits of approximately $1.6 million. Included in the unrecognized tax benefits were $1.3 million of tax benefits that, if recognized, would have a favorable impact on our annual effective tax rate, subject to the valuation allowance. We do not expect our unrecognized tax benefits to change significantly over the next 12 months.

We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2008; however, our net operating loss and research credit carry-forwards arising prior to that year are subject to adjustment. It is our policy to recognize interest expense and penalties related to income tax matters as a component of income tax expense.

XML

Financial Instruments

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Financial Instruments

Financial Instruments

Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2014 and December 31, 2013.

	Fair Value as of March 31, 2014
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Corporate debt securities	$	—	$	9,871	$	—	$	9,871
Liabilities:
Acquisition related contingent consideration	$	—	$	—	$	220	$	220

	Fair Value as of December 31, 2013
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Corporate debt securities	$	—	$	7,673	$	—	$	7,673

The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. We did not reclassify any investments between levels in the fair value hierarchy during the three months ended March 31, 2014.

The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014 (See Note 3).  We will reassess the fair value of the contingent consideration to be settled in cash related to our acquisition of Telerhythmics on a quarterly basis using the income approach, which is a Level 3 measurement. Significant assumptions used in the measurement include probabilities of achieving the EBITDA milestones.

Securities Available for Sale

Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the three months ended March 31, 2014 and 2013.

The following table sets forth the composition of securities available-for-sale as of March 31, 2014 and December 31, 2013.

	Maturity in Years	Amortized Cost		Unrealized					Fair Value
As of March 31, 2014 (in thousands)				Gains		Losses
Corporate debt securities	3 or less	$	9,891	$	6	$	(26	)	$	9,871
	Maturity in Years	Amortized Cost		Unrealized					Fair Value
As of December 31, 2013 (in thousands)				Gains		Losses
Corporate debt securities	3 or less	$	7,675	$	—	$	(2	)	$	7,673

XML

Commitments And Contingencies

3 Months Ended

Mar. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Leases

We currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from April 1, 2014 through February 28, 2021. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other liabilities. Rent expense was approximately $0.4 million for the three months ended March 31, 2014 and 2013.

As of March 31, 2014, we financed certain information technology and medical equipment and vehicles under capital leases. These obligations are secured by the specific equipment financed under each lease and will be repaid monthly over the remaining lease terms through March 31, 2018.

The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of March 31, 2014 are as follows (in thousands):

	Operating Leases		Capital Leases
2014	$	662	$	161
2015	883		214
2016	522		140
2017	258		24
2018	215		3
2019	221		—
Thereafter	266		—
Total minimum lease payments	$	3,027	$	542

Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

XML

Segments

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Segments

Segments

Our reportable segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.

On March 13, 2014, we acquired all the outstanding membership interest of Telerhythmics, LLC (See Note 3). As part of the acquisition, we evaluated Telerhythmics' business operations, both on a quantitative and qualitative basis, and determined its business operations appropriately met the criteria to be aggregated with our Diagnostic Services business in accordance with the authoritative accounting guidance for segment reporting. The Diagnostic Services reportable segment was renamed in conjunction with the acquisition from Digirad Imaging Solutions.

The financial results below for the three months ended March 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014.

	Three Months Ended March 31,
(in thousands)	2014			2013
Gross profit by segment:
Diagnostic Services	$	2,021		$	2,114
Diagnostic Imaging	1,421			703
Condensed consolidated gross profit	$	3,442		$	2,817
Income (loss) from operations by segment:
Diagnostic Services	$	(333	)	$	(144	)
Diagnostic Imaging (1)	178			(2,265		)
Condensed consolidated loss from operations	$	(155	)	$	(2,409	)
Depreciation and amortization:
Diagnostic Services	$	375		$	392
Diagnostic Imaging	78			101
Condensed consolidated depreciation and amortization	$	453		$	493

(in thousands)	As of March 31, 2014		As of December 31, 2013
Identifiable assets by segment:
Diagnostic Services	$	15,172	$	11,874
Diagnostic Imaging	25,387		29,577
Condensed Consolidated assets	$	40,559	$	41,451

⁽¹⁾Included in the Diagnostic Imaging income (loss) from operations for the three months ended March 31, 2014 and 2013, are approximately $0.4 million and $1.0 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7).

XML

Intangibles and Goodwill (Details) (USD $)	3 Months Ended			3 Months Ended	12 Months Ended	3 Months Ended		12 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014 Customer Relationships [Member]	Dec. 31, 2013 Customer Relationships [Member]	Mar. 31, 2014 Trademarks [Member]	Mar. 31, 2014 Patents [Member]	Dec. 31, 2013 Patents [Member]	Mar. 31, 2014 Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill, Gross	$ 1,459,000		$ 184,000
Goodwill	1,459,000		184,000
Finite-Lived Intangible Asset, Useful Life				8 years 3 months 18 days	3 years 6 months	8 years 11 months 15 days	4 years 9 months 18 days	4 years 10 months 24 days	4 years 11 months 15 days
Finite-Lived Intangible Assets, Gross	5,661,000		3,081,000	4,850,000	2,940,000	600,000	141,000	141,000	70,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,794,000)		(2,728,000)	(2,682,000)	(2,622,000)	(3,000)	(108,000)	(106,000)	(1,000)
Finite-Lived Intangible Assets, Net	2,867,000		353,000	2,168,000	318,000	597,000	33,000	35,000	69,000
Amortization of intangible assets	66,000	66,000
2014	300,000
2015	400,000
2016	400,000
2017	400,000
2018	300,000
Thereafter	$ 1,200,000

XML

Acquisition of Telerhythmics (Tables)

3 Months Ended

Mar. 31, 2014

Business Combinations [Abstract]

Schedule of Purchase Price Allocation

	March 13, 2014
Assets
Current assets:
Accounts receivable, net	$	200
Other current assets	41
Total current assets	241
Property and equipment, net	290
Intangible assets, net	2,580
Goodwill	1,275
Total assets	$	4,386
Accounts payable	$	36
Accrued compensation	169
Other accrued liabilities	356
Current portion of long-term debt	131
Total current liabilities	692
Other liabilities	174
Total liabilities	$	866

Business Acquisition, Pro Forma Information

	Three Months Ended March 31, 2014						Three Months Ended March 31, 2013
	Digirad		Telerhythmics		Proforma		Digirad			Telerhythmics			Proforma
Revenues	$	12,742	$	1,410	$	14,152	$	11,546		$	1,413		$	12,959
Net income (loss)	$	19	$	7	$	26	$	(2,419	)	$	(115	)	$	(2,534	)

Schedule of Condensed Income Statement

	March 14, 2014 - March 31, 2014
Revenues	$	255
Net loss	$	(167	)

XML

Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques

The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2014 and December 31, 2013.

	Fair Value as of March 31, 2014
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Corporate debt securities	$	—	$	9,871	$	—	$	9,871
Liabilities:
Acquisition related contingent consideration	$	—	$	—	$	220	$	220

	Fair Value as of December 31, 2013
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Corporate debt securities	$	—	$	7,673	$	—	$	7,673

Available-for-sale Securities

The following table sets forth the composition of securities available-for-sale as of March 31, 2014 and December 31, 2013.

	Maturity in Years	Amortized Cost		Unrealized					Fair Value
As of March 31, 2014 (in thousands)				Gains		Losses
Corporate debt securities	3 or less	$	9,891	$	6	$	(26	)	$	9,871
	Maturity in Years	Amortized Cost		Unrealized					Fair Value
As of December 31, 2013 (in thousands)				Gains		Losses
Corporate debt securities	3 or less	$	7,675	$	—	$	(2	)	$	7,673

XML

Income Tax (Details) (USD $) In Millions, unless otherwise specified	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 1.6
Unrecognized tax benefits that would impact effective tax rate	$ 1.3

XML

Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating activities
Net loss	$ (148)	$ (2,419)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	387	427
Amortization of intangible assets	66	66
Provision for bad debt	21	11
Stock-based compensation	50	121
Gain on sale of assets	5	0
Amortization of premiums on investments	51	46
Changes in operating assets and liabilities:
Accounts receivable	(1,699)	500
Inventories	293	130
Other assets	70	(89)
Accounts payable	449	352
Accrued compensation	(1,019)	252
Deferred revenue	(250)	(369)
Other liabilities	168	(197)
Restricted cash	(233)	0
Net cash used in operating activities	(1,789)	(1,169)
Investing activities
Purchases of property and equipment	(571)	(189)
Purchases of securities available-for-sale	(2,617)	(4,679)
Sales and maturities of securities available-for-sale	350	2,050
Net cash paid for acquisition	(3,470)	0
Net cash used in investing activities	(6,308)	(2,818)
Financing activities
Issuances of common stock	0	29
Repurchases of common stock	0	(20)
Dividend paid	(925)
Repayment of long-term debt	(131)
Repayment of obligations under capital leases	42	0
Net cash provided by (used in) financing activities	(1,098)	9
Net decrease in cash and cash equivalents	(9,195)	(3,978)
Cash and cash equivalents at beginning of period	18,744	19,514
Cash and cash equivalents at end of period	$ 9,549	$ 15,536

XML

Property and Equipment (Notes)

3 Months Ended

Mar. 31, 2014

Property and Equipment [Abstract]

Property and Equipment

Property and Equipment

(in thousands)	March 31, 2014			December 31, 2013
Machinery and equipment	$	23,216		$	22,596
Computer hardware and software	2,520			2,497
Leasehold improvements	900			861
	26,636			25,954
Accumulated depreciation	(22,122		)	(21,801		)
Property and equipment, net	$	4,514		$	4,153

XML

Commitments And Contingencies Leases (Tables)

3 Months Ended

Mar. 31, 2014

Leases [Abstract]

Schedule of Property Subject to or Available for Operating Lease

	Operating Leases		Capital Leases
2014	$	662	$	161
2015	883		214
2016	522		140
2017	258		24
2018	215		3
2019	221		—
Thereafter	266		—
Total minimum lease payments	$	3,027	$	542

XML

Financial Instruments Assets and Liabilities at Fair Value on a Recurring Basis (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition related contingent consideration	$ 0
Level 1 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition related contingent consideration	0
Level 2 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	9,871	7,673
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition related contingent consideration	220
Level 3 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	0	0
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition related contingent consideration	220
Total | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities	$ 9,871	$ 7,673

XML

Schedule of Earnings Per Share, Basic and Diluted (Tables)

3 Months Ended

Mar. 31, 2014

Earnings Per Share, Basic and Diluted [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the reconciliation of shares used to compute basic and diluted net loss per share for the periods indicated:

	Three Months Ended March 31,
(shares in thousands)	2014	2013
Weighted average shares outstanding - basic	18,518	19,322
Dilutive potential common stock outstanding:
Stock options	—	—
Restricted stock units	—	—
Weighted average shares outstanding - diluted	18,518	19,322

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net loss per share because their effect was anti-dilutive:

	Three Months Ended March 31,
(shares in thousands)	2014	2013
Stock options	373	303
Restricted stock units	—	16
Total	373	319